S095035
Total Payments
$31,725
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $31,725 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31,725 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene | Servier BioInnovation | $31,725 | 0 |
Top Doctors Receiving Payments for S095035
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Antonio, TX | $31,725 | 4 |
Ad
Manufacturing Companies
- Servier BioInnovation $31,725
Product Information
- Type Drug
- Total Payments $31,725
- Total Doctors 0
- Transactions 4
About S095035
S095035 is a drug associated with $31,725 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Servier BioInnovation.
Payment data is available from 2024 to 2024. In 2024, $31,725 was paid across 4 transactions to 0 doctors.
The most common payment nature for S095035 is "Unspecified" ($31,725, 100.0% of total).
S095035 is associated with 1 research study, including "S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene" ($31,725).